目录产品 » HLA-A*01:01&B2M&DSG3 (YTDNWLAVY) Monomer, His & Avi, Human
Manual
SDS
COAs

HLA-A*01:01&B2M&DSG3 (YTDNWLAVY) Monomer, His & Avi, Human

DSG3 is overexpressed in head neck cancer and is a potential molecular target for inhibition of oncogenesis. DSG3 is identified overexpressed in HNC, with the degree of overexpression associated with clinicopathologic features of the tumor. Inhibition of DSG3 significantly suppresses carcinogenic potential in cellular and in vivo animal studies. These findings suggest that DSG3 is a potential molecular target in the development of adjuvant therapy for HNC.
￥3000
Z06547-100

产品简介
Species Human
Protein Construction
HLA-A*01:01&B2M&DSG3 (YTDNWLAVY) Monomer [Gly25-Thr305(HLA-A*01:01), Ile21-Met119(B2M) and YTDNWLAVY peptide]
Accession # Q5SUL5(HLA-A*01:01)&P61769(B2M)&YTDNWLAVY		 His Avi
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 50.50 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 52-62 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.
返回

技术背景
Target Background DSG3 is overexpressed in head neck cancer and is a potential molecular target for inhibition of oncogenesis. DSG3 is identified overexpressed in HNC, with the degree of overexpression associated with clinicopathologic features of the tumor. Inhibition of DSG3 significantly suppresses carcinogenic potential in cellular and in vivo animal studies. These findings suggest that DSG3 is a potential molecular target in the development of adjuvant therapy for HNC.
Synonyms DSG3; DSG-3; Desmoglein-3; PVA; CDHF6; DG3
返回

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.